The text discusses the importance of screening for DPD deficiency before prescribing 5-FU-based chemotherapy for non-metastatic colon cancer patients. Screening for DPD deficiency is recommended by various organizations to prevent severe adverse reactions to fluoropyrimidines. If a patient has a uracil level of 150 ng/ml or higher, fluoropyrimidines should be avoided, or used at a very low dose with close monitoring.